

ISSN 2518-1629 (Online),
ISSN 2224-5308 (Print)

ҚАЗАҚСТАН РЕСПУБЛИКАСЫ
ҰЛТТЫҚ ҒЫЛЫМ АКАДЕМИЯСЫНЫҢ
Өсімдіктердің биологиясы және биотехнологиясы институтының

Х А Б А Р Л А Р Ы

ИЗВЕСТИЯ

НАЦИОНАЛЬНОЙ АКАДЕМИИ НАУК
РЕСПУБЛИКИ КАЗАХСТАН
Института биологии и биотехнологии растений

NEWS

OF THE NATIONAL ACADEMY OF SCIENCES
OF THE REPUBLIC OF KAZAKHSTAN
of the Institute of Plant Biology and Biotechnology

**БИОЛОГИЯ ЖӘНЕ МЕДИЦИНА
СЕРИЯСЫ**



СЕРИЯ

БИОЛОГИЧЕСКАЯ И МЕДИЦИНСКАЯ



SERIES

OF BIOLOGICAL AND MEDICAL

5 (317)

**ҚЫРКҮЙЕК – ҚАЗАН 2016 ж.
СЕНТЯБРЬ – ОКТЯБРЬ 2016 г.
SEPTEMBER – OCTOBER 2016**

**1963 ЖЫЛДЫҢ ҚАҢТАР АЙЫНАН ШЫҒА БАСТАҒАН
ИЗДАЕТСЯ С ЯНВАРЯ 1963 ГОДА
PUBLISHED SINCE JANUARY 1963**

**ЖЫЛЫНА 6 РЕТ ШЫҒАДЫ
ВЫХОДИТ 6 РАЗ В ГОД
PUBLISHED 6 TIMES A YEAR**

**АЛМАТЫ, ҚР ҰҒА
АЛМАТЫ, НАН РК
ALMATY, NAS RK**

Б а с р е д а к т о р

ҚР ҰҒА академигі, м. ғ. д., проф.

Ж. А. Арзықұлов

Абжанов Архат проф. (Бостон, АҚШ),
Абелев С.К. проф. (Мәскеу, Ресей),
Айтқожина Н.А. проф., академик (Қазақстан)
Акшулаков С.К. проф., корр.-мүшесі (Қазақстан)
Алшынбаев М.К. проф., корр.-мүшесі (Қазақстан)
Березин В.Э., проф., корр.-мүшесі (Қазақстан)
Бисенбаев А.К. проф., корр.-мүшесі (Қазақстан)
Бишимбаева Н.К. проф., корр.-мүшесі (Қазақстан)
Ботабекова Т.К. проф., корр.-мүшесі (Қазақстан)
Bosch Ernesto prof. (Spain)
Ellenbogen Adrian prof. (Tel-Aviv, Israel),
Жамбакин К.Ж. проф., корр.-мүшесі (Қазақстан), бас ред. орынбасары
Ishchenko Alexander, prof. (Villejuif, France)
Қайдарова Д.Р. проф., корр.-мүшесі (Қазақстан)
Күзденбаева Р.С. проф., академик (Қазақстан)
Лось Д.А. prof. (Мәскеу, Ресей)
Lunefeld Bruno prof. (Израиль)
Миербеков Е.М. проф. (Қазақстан)
Муминов Т.А. проф., академик (Қазақстан)
Purton Saul prof. (London, UK)
Рахыпбеков Т.К. проф., корр.-мүшесі (Қазақстан)
Сапарбаев Мұрат проф. (Париж, Франция)
Сарбассов Дос проф. (Хьюстон, АҚШ)

«ҚР ҰҒА Хабарлары. Биология және медициналық сериясы».

ISSN 2518-1629 (Online),

ISSN 2224-5308 (Print)

Меншіктенуші: «Қазақстан Республикасының Ұлттық ғылым академиясы» РҚБ (Алматы қ.)

Қазақстан республикасының Мәдениет пен ақпарат министрлігінің Ақпарат және мұрағат комитетінде
01.06.2006 ж. берілген №5546-Ж мерзімдік басылым тіркеуіне қойылу туралы куәлік

Мерзімділігі: жылына 6 рет.

Тиражы: 300 дана.

Редакцияның мекенжайы: 050010, Алматы қ., Шевченко көш., 28, 219 бөл., 220, тел.: 272-13-19, 272-13-18,
www.nauka-nanrk.kz / biological-medical.kz

© Қазақстан Республикасының Ұлттық ғылым академиясы, 2016

Типографияның мекенжайы: «Аруна» ЖК, Алматы қ., Муратбаева көш., 75.

Г л а в н ы й р е д а к т о р
академик НАН РК, д.м.н., проф.

Ж. А. Арзыкулов

Абжанов Архат проф. (Бостон, США),
Абелев С.К. проф. (Москва, Россия),
Айтхожина Н.А. проф., академик (Казахстан)
Акшулаков С.К. проф., чл.-корр. (Казахстан)
Алчинбаев М.К. проф., чл.-корр. (Казахстан)
Березин В.Э., проф., чл.-корр. (Казахстан)
Бисенбаев А.К. проф., чл.-корр. (Казахстан)
Бишимбаева Н.К. проф., чл.-корр. (Казахстан)
Ботабекова Т.К. проф., чл.-корр. (Казахстан)
Bosch Ernesto prof. (Spain)
Ellenbogen Adrian prof. (Tel-Aviv, Israel),
Жамбакин К.Ж. проф., чл.-корр. (Казахстан), зам. гл. ред.
Ishchenko Alexander prof. (Villejuif, France)
Кайдарова Д.Р. проф., чл.-корр. (Казахстан)
Кузденбаева Р.С. проф., академик (Казахстан)
Лось Д.А. prof. (Москва, Россия)
Lunenfeld Bruno prof. (Израиль)
Миербеков Е.М. проф. (Казахстан)
Муминов Т.А. проф., академик (Казахстан)
Purton Saul prof. (London, UK)
Рахыпбеков Т.К. проф., чл.-корр. (Казахстан)
Сапарбаев Мурат проф. (Париж, Франция)
Сарбассов Дос проф. (Хьюстон, США)

«Известия НАН РК. Серия биологическая и медицинская».

ISSN 2518-1629 (Online),

ISSN 2224-5308 (Print)

Собственник: РОО «Национальная академия наук Республики Казахстан» (г. Алматы)

Свидетельство о постановке на учет периодического печатного издания в Комитете информации и архивов
Министерства культуры и информации Республики Казахстан №5546-Ж, выданное 01.06.2006 г.

Периодичность: 6 раз в год

Тираж: 300 экземпляров

Адрес редакции: 050010, г. Алматы, ул. Шевченко, 28, ком. 219, 220, тел. 272-13-19, 272-13-18,

www.nauka-nanrk.kz/biological-medical.kz

© Национальная академия наук Республики Казахстан, 2016

Адрес типографии: ИП «Аруна», г. Алматы, ул. Муратбаева, 75

Editor in chief

academician of NAS RK, doctor of medical science, professor

Zh. A. Arzykulov

Abzhanov Arkhat prof. (Boston, USA),
Abelev S.K. prof. (Moscow, Russia),
Aitkhozhina N.A. prof., academician (Kazakhstan)
Akshulakov S.K. prof., corr. member. (Kazakhstan)
Alchinbayev M.K. prof., corr. member. (Kazakhstan)
Berezin V.Ye., prof., corr. member. (Kazakhstan)
Bisenbayev A.K. prof., corr. member. (Kazakhstan)
Bishimbayeva N.K. prof., corr. member. (Kazakhstan)
Botabekova T.K. prof., corr. member. (Kazakhstan)
Bosch Ernesto prof. (Spain)
Ellenbogen Adrian prof. (Tel-Aviv, Israel),
Zhambakin K.Zh. prof., corr. member. (Kazakhstan), deputy editor in chief
Ishchenko Alexander, prof. (Villejuif, France)
Kaydarova D.R. prof., corr. member. (Kazakhstan)
Kuzdenbayeva R.S. prof., academician (Kazakhstan)
Los D.A. prof. (Moscow, Russia)
Lunenfeld Bruno prof. (Israel)
Miyerbekov Ye.M. prof. (Kazakhstan)
Muminov T.A. prof., academician (Kazakhstan)
Purton Saul prof. (London, UK)
Rakhypbekov T.K. prof., corr. member. (Kazakhstan)
Saparbayev Murat prof. (Paris, France)
Sarbassov Dos, prof. (Houston, USA)

News of the National Academy of Sciences of the Republic of Kazakhstan. Series of biology and medicine.

ISSN 2518-1629 (Online),

ISSN 2224-5308 (Print)

Owner: RPA "National Academy of Sciences of the Republic of Kazakhstan" (Almaty)

The certificate of registration of a periodic printed publication in the Committee of information and archives of the Ministry of culture and information of the Republic of Kazakhstan N 5546-Ж, issued 01.06.2006

Periodicity: 6 times a year

Circulation: 300 copies

Editorial address: 28, Shevchenko str., of. 219, 220, Almaty, 050010, tel. 272-13-19, 272-13-18,
<http://nauka-nanrk.kz> / biological-medical.kz

© National Academy of Sciences of the Republic of Kazakhstan, 2016

Address of printing house: ST "Aruna", 75, Muratbayev str, Almaty

NEWS

OF THE NATIONAL ACADEMY OF SCIENCES OF THE REPUBLIC OF KAZAKHSTAN

SERIES OF BIOLOGICAL AND MEDICAL

ISSN 2224-5308

Volume 5, Number 317 (2016), 30 – 35

UDC 616.858: 616.89-008.3-089

**S. K. Akshulakov, Ch. S. Shashkin, Y. T. Makhambetov,
B. D. Djamantayeva, V. K. Akhmetzhanov, A. S. Shpekov**

“National Center for neurosurgery” JSC, Astana, Kazakhstan.

E-mail: serik.akshulakov@nmh.kz, chingiz.shashkin@nmh.kz, erbol.mahambetov@nmh.kz,
botagoz.dzhamentaeva@nmh.kz, vadim.akhmetzhanov@nmh.kz, azat.shpekov@nmh.kz

**DEEP BRAIN STIMULATION
FOR MOVEMENT DISORDERS TREATMENT**

Abstract. Deep brain stimulation (DBS) is the electrical stimulation of the deep nuclei. Electrodes implanted in the desired target and the stimulation parameters can be modified to enhance the positive and to reduce side effects. Mostly often such diseases as Parkinson's disease, essential tremor and dystonia are treated by DBS.

Tremor and rigidity in Parkinson's disease is treatable especially by stimulation of the subthalamic nucleus. Stimulation of the ventral nucleus of the thalamus is the most effective method of treatment of essential tremor. The stimulation of the globus pallidus showed to be effective in primary generalized dystonia, primary segmental dystonia, cervical dystonia, blepharospasm, Merge syndrome, tardive dystonia and certain forms of secondary dystonia.

128 patients with movement disorders were operated in the National Center for neurosurgery in the period from 2013 to 2015. 117 patients out of 128 were operated with the diagnosis of Parkinson's disease, 10 with dystonia, 1 with essential tremor. There were 57 men and 72 women. The average patient age was 51 year. A significant improvement in motor function in patients operated on Parkinson's disease increased by 65% in 2013 and 71% in 2014 to 92% in 2015. DBS treatment of patients with dystonia was significantly effective in spastic torticollis, but it is less effective in patients with secondary generalized and segmentary dystonia.

The National Center for Neurosurgery has been providing the movement disorders surgery program for 3 years.

Keywords: deep brain stimulation, Parkinson's disease, dystonia, tremor, surgical treatment.

Introduction. Surgical treatment of medically refractory forms of movement disorders lay in the destruction of neural structures involved in the process, usually the thalamus or pallidum. Thus small areas destruction is made by chemical degradation, freeze coagulation or electrical. Since a permanent hotbed of destruction developed after these procedures, if it is successful, the effect would be permanent, but if unsuccessful, the side effects would be very severe and irreversible.

Deep brain stimulation (DBS) is a high-frequency electrical stimulation of the underlying nuclei and causes the same therapeutic effect as with destruction. DBS method appeared in the 1960s. In the 1970s, a method was developed and began to be used in the treatment of pain syndromes, epilepsy, movement disorders and cerebral palsy [1, 2]. Currently, the method of DBS treats, in addition to movement disorders, Tourette's syndrome, depression, obsessive-compulsive disorders [3].

DBS has advantages over the destruction due to its adjustability and reversibility. Electrodes are implanted in the desired goal, but the stimulation parameters can be modified to enhance the positive effects and to reduce side. If the treatment is ineffective, the electrodes can be repositioned or removed altogether, without any consequences. In view of the above, the DBS has become the method of choice for the treatment of movement disorders, as compared to the currently used destructive operations [4]. Mostly often Parkinson's disease, essential tremor and dystonia are treated with DBS method.

Parkinson's disease. Parkinson's disease (PD) is the second most common neurodegenerative disease that affects between 1 and 3% of adults older than 65 years old [5]. The tremor, bradykinesia and rigidity - the main symptoms of Parkinson's disease. In spite of the therapy, in 40% of patients disease symptoms are saved and 28% experience levodopa-induced dyskinesia [6].

Traditional treatment with levodopa gives a positive effect, but long-term use develops side effects. Dyskinesia, a condition where the patient experiences a spontaneous involuntary movements are the most common side effect, and is also a limiting factor of levodopa therapy. DBS of subthalamic nucleus or globus pallidus cropped PD symptoms, leading to a reduction in the dose of levodopa, thereby reduce dyskinesia. The best candidates for DBS are patients with severe motor parkinsonian syndrome in the «off» stage, an improvement from the antiparkinsonian therapy, but with levodopa-induced movement disorders with a history of the disease for more than 5 years. Candidates for DBS should not have rude cognitive impairment or dementia [7-9].

Stimulation of the ventral nucleus of the thalamus (nucleus ventralis intermedius thalami, VIM) is used in a limited number of patients with PD-tremor predominant because it has insufficient effect on rigidity and bradykinesia, the most common symptoms of PD [10,11]. The stimulation of the globus pallidus (globus pallidus interna, GPi) is also effective for the treatment of tremor, but also reduces symptoms of dyskinesia, rigidity and bradykinesia, postural stability somewhat improved [12]. Stimulation of the subthalamic nucleus (subthalamic nucleus, STN) is similar to GPi stimulation in terms of rigidity, bradykinesia and tremor treatment, and also results in reduction in the dose of antiparkinsonian drugs, which reduces dyskinesia pharmacological [13]. STN stimulation is fairly well studied and is therefore a more advanced procedure [14]. Tremor and rigidity is particularly amenable to treatment by STN stimulation, and bradykinesia, gait disturbances, and postural instability. Improvement by 50% motor UPDRS scale after STN stimulation was maintained for 5 years [15]. STN stimulation allows in 50-60% cases to reduce the dose of the dopaminergic agents, thereby reducing dyskinesia in 94% of cases after 12 months of treatment [14,16]. The results of 2 randomized studies comparing best medical therapy with STN and GPi stimulation showed that patients who received STN and GPi stimulation watched in addition more than 4 hours «on» period without medication dyskinesias [17]. Another study compared the stimulation of STN and GPi. They found that in the off-stage rigidity, bradykinesia and tremor were decreased during stimulation of both structures. Dyskinesia is also decreased for 12 months after surgery. However, bradykinesia was better treated by STN stimulation, and these patients have reduced the dose of antiparkinsonian drugs longer than patients who received GPi stimulation [19]. The comparison study of unilateral STN and GPi stimulation found no changes in mood or cognitive abilities [20]. Since PD - progressing disease, reducing of response of treatment may occur with the progression of the disease or as a result of adaptation to stimulation.

Essential tremor. Essential tremor (ET) is also known as benign tremor or familial tremor, is one of the most common movement disorders, affects more than 5% of the population over 60, but can occur at any age [21]. Over time, the ET can significantly reduce quality of life, leading to the fact that patients need help with eating and daily activities.

Drug ET treatment is usually with beta-blocking agent, such as propranolol. Anticonvulsants, ethanol and some benzodiazepines may be effective to reduce tremors. However, 50% of patients with ET do not respond to medical therapy [21]. With the recording microelectrodes it was revealed that cells in "VIM" light at the same frequency with which tremor occurs, and can be regarded as Targeted cells [26]. High frequency stimulation via electrode can suppress the abnormal activity, thereby reducing tremor. Unilateral and bilateral tremor of the extremities, face, vocal cords and tongue may be treated by VIM stimulation. Usually in practice, a bilateral VIM stimulation is used [23,24,25]. Many prospective studies have demonstrated the high efficiency of VIM stimulation in the treatment of ET [23,27,28,29]. Most patients report a significant reduction in tremor in the limbs from 50% to 80%. Although about 9% of patients with radiologically verified correct position of electrodes have no positive result [30,31].

Dystonia. Dystonia – is a movement disorder characterized by prolonged involuntary muscle contractions in the trunk or limbs. Neurophysiological studies indicate that the co-contraction of muscles of agonists and antagonists is responsible for dystonic position [32]. Primary dystonia has a hereditary nature and is associated with DYT genes [33]. Secondary dystonia appears after the well-known reasons. The prevalence of focal dystonia - 29.5 per 100,000 population, primary generalized dystonia 3.4 per 100,000 [34].

Drug treatment of dystonia is in the application of anticholinergic drugs, benzodiazepines and other preparations. However, the success of drug therapy varies from 20% to 40% [35,36]. Medication has a number of side effects such as sedation, Parkinsonism, cognitive dysfunction [37]. Treatment of focal

dystonia forms of botulinum toxin A, which has been the main treatment for dystonia to the 1980s, led to a good clinical effect. However, long-term use of botulinum toxin A is limited due to the follow immuno-resistance thereto and reduce the effect of treatment [37, 38].

DBS for dystonia treatment showed to be effective in improving the symptoms of the disease. The main candidates for DBS - are patients with dystonia, the symptoms of which severely limit normal life, despite taking medication. The main criteria for inclusion in the DBS treatment group: age older than 7 years, primary dystonia, including generalized and segmental form, spasmodic torticollis [39]. The target of DBS is postventral lateral portion of GPi [40]. GPi stimulation showed to be effective in primary generalized dystonia, primary segmental dystonia, cervical dystonia, blepharospasm, Meige syndrome, tardive dystonia and certain forms of secondary dystonia [41].

Materials and methods of research. In the National center for neurosurgery there were operated 128 patients with movement disorders in the period from 2013 to 2015. Among them 117 patients were operated with the diagnosis of Parkinson's disease, 10 with dystonia, 1 with essential tremor. There were 57 men and 72 women. The average patient age was 51. In 116 cases, the aim was to stimulate the subthalamic nucleus (STN), in 12 cases - the globus pallidus (GPi) and in 1 case - the ventral thalamus (VIM). 73 operated patients were observed for more than 1 year.

We have used international criteria for the selection of patients with Parkinson's disease to the DBS. Their clinical status was assessed using the Unified Parkinson's Disease Rating Scale. The mean duration of disease was 10 years. Pronounced motor fluctuations and dyskinesias were in 75% of patients.

The main indication for DBS with a view to the globus pallidus was focal dystonia with spasmodic torticollis.

For the implantation of electrodes it was used multipurpose stereotactic frame and G-frame arch (Electa, Sweden) and SurgiPlan software (Elekta, Sweden) [42].

For implantation it was used Activa PC of the company Medtronic (USA, Minneapolis) system for deep brain stimulation, which consists of two electrodes, two extension cables and pulse generator.

The vast majority of implantations (90%) was carried out using the microelectrode recording of the LeadPoint Micro Electrode Recording (MER) system manufactured by Medtronic (USA, Minneapolis).

Results. Significant improvement of motor functions (more than 50% in the Unified Parkinson's Disease Rating Scale) in patients operated on for Parkinson's disease has increased from 65% in 2013 and from 71% in 2014 to 92% in 2015. Postural instability, gait problems and standalone symptoms regressed less. We reduced the dose of dopaminergic drugs by 30-50%, which allowed to neutralize levodopa-induced dyskinesia in all cases. 6 patients were to completely abandon the levodopa therapy.

DBS treatment of patients with dystonia was significantly effective in spastic torticollis, but was less effective in patients with secondary segmentary and generalized dystonia.

Patient with essential tremor got rid of it, but not completely.

In 12 cases, we observed various surgical complications in patients with implanted devices. In 1 case it was symptomatic hemorrhage occurred during the installation of the electrode, which resulted in hemiparesis. In two cases there was asymptomatic hemorrhage. In 7 cases, there was infection contamination of the system that caused the complete removal of the system 4 and partially in 3 cases. Two patients developed a pulmonary embolism, which ended lethally in one patient. The number of complications was reduced as gaining experience and developing a protocol of diagnosis and treatment based on evidence-based medicine. Devices complications not observed.

Conclusion. In the National center for neurosurgery for 3 years it has been held the program of treatment of patients with movement disorders by DBS.

Deep brain stimulation has become an important part of the treatment of movement disorders including Parkinson's disease, essential tremor and dystonia. For patients whose symptoms are not amenable to drug therapy, DBS is the method of choice. The majority of patients who received DBS at the National center of neurosurgery, greatly stopped major disabling symptoms of diseases and increased quality of life. Of great importance is the correct patient selection, which allows to achieve the best outcomes.

REFERENCES

- [1] Cooper, I., 1973. Effect of chronic stimulation of anterior cerebellum on neurological disease. *Lancet* 1, -206. doi:10.1016/S0140-6736(73)91338-X
- [2] Cooper, I., et al., 1976. Chronic cerebellar stimulation in cerebral palsy. *Neurology* 26, 744–753. doi: <http://dx.doi.org/10.1212/WNL.26.8.744>
- [3] Lipsman, N., et al., 2007. Deep brain stimulation for treatment-refractory obsessive compulsive disorder: The search for a valid target. *Neurosurgery* 61, 1–11. doi: 10.1227/01.neu.0000279719.75403.f7
- [4] Okun, M., Vitek, J., 2004. Lesion therapy for Parkinson's disease and other movement disorders: update and controversies. *Mov. Disord.* 19, 375–389. DOI: 10.1002/mds.20037
- [5] Twelves, D., Perkins, K.S.M., Counsell, C., 2003. Systematic review of incidence studies of Parkinson's disease. *Mov. Disord.* 18, 19–31. DOI: 10.1002/mds.10305
- [6] Schrag, A., Quinn, N., 2000. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. *Brain* 123, 2297–2305. DOI: <http://dx.doi.org/10.1093/brain/123.11.2297> 2297-2305
- [7] Alegret, M., et al., 2001. Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. *Arch. Neurol.* 58, 1223–1227. doi:10.1001/archneur.58.8.1223.
- [8] Parsons, T., et al., 2006. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. *Lancet Neurol.* 5, 578–588. doi:10.1016/S1474-4422(06)70475-6
- [9] Saint-Cyr, J.A., et al., 2000. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. *Brain* 123 (Pt 10), 2091–2108. DOI: <http://dx.doi.org/10.1093/brain/123.10.2091> 2091-2108
- [10] Kumar, R., et al., 2003. Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. *Neurology* 61, 1601–1604. doi: <http://dx.doi.org/10.1212/01.WNL.0000096012.07360.1C>
- [11] Rehnrcrona, S., et al., 2003. Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments. *Mov. Disord.* 18, 163–170. DOI: 10.1002/mds.10309
- [12] Obeso, J., et al., 2001. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *N. Engl. J. Med.* 345, 956–963. DOI: 10.1056/NEJMoa000827
- [13] Limousin, P., et al., 1998. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N. Engl. J. Med.* 339, 1105–1111. DOI: 10.1056/NEJM199810153391603
- [14] Hamani, C., et al., 2005. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review the clinical literature. *Neurosurgery* 56, 1313–1321. doi: 10.1227/01.NEU.0000159714.28232.C4
- [15] Krack, P., et al., 2003. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N. Engl. J. Med.* 349, 1925–1934. DOI: 10.1056/NEJMoa035275
- [16] Kleiner-Fisman, G., et al., 2006. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. *Mov. Disord.* 21, S290–S304. DOI: 10.1002/mds.20962
- [17] Deuschl, G., et al., 2006. A randomized trial of deep-brain stimulation for Parkinson's disease. *N. Engl. J. Med.* 355, 896–908. DOI: 10.1056/NEJMs060054
- [18] Weaver, F., et al., 2009. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. *JAMA* 301, 63–73. doi:10.1001/jama.2008.929
- [19] Anderson, V.C., et al., 2005. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. *Arch. Neurol.* 62, 554–560. doi:10.1001/archneur.62.4.554.
- [20] Okun, M.S., et al., 2009. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE trial. *Ann. Neurol.* 65, 586–595. DOI: 10.1002/ana.21596
- [21] Lyons, K.E., Pahwa, R., 2004. Deep brain stimulation and essential tremor. *J. Clin. Neurophys.* 21, 2–5. <http://journals.lww.com/clinicalneurophys/pages/articleviewer.aspx?year=2004&issue=01000&article=00002&type=abstract>
- [22] Carpenter, M.A., et al., 1998. Reduction in voice tremor under thalamic stimulation. *Neurology* 50, 796–798. doi: <http://dx.doi.org/10.1212/WNL.50.3.796>
- [23] Hariz, G.M., et al., 2008a. Long-term effect of deep brain stimulation for essential tremor on activities of daily living and health-related quality of life. *Acta Neurol. Scand.* 118, 387–394. DOI: 10.1111/j.1600-0404.2008.01065.x
- [24] Obwegeser, A.A., et al., 2000. Thalamic stimulation for the treatment of midline tremors in essential tremor patients. *Neurology* 54, 2342–2344. doi: <http://dx.doi.org/10.1212/WNL.54.12.2342>
- [25] Ondo, W., et al., 2001. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. *Arch. Neurol.* 58, 218–222. doi:10.1001/archneur.58.2.218.
- [26] Lenz, F.A., et al., 1994. Single-unit analysis of the human ventral thalamic nuclear group: tremor-related activity in functionally identified cells. *Brain* 117, 531–543. DOI: <http://dx.doi.org/10.1093/brain/117.3.531> 531-543
- [27] Limousin, P., et al., 1999. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. *J. Neurol. Neurosurg. Psychiatry* 66, 289–296. doi:10.1136/jnnp.66.3.289
- [28] Pahwa, R., et al., 2006. Long-term evaluation of deep brain stimulation of the thalamus. *J. Neurosurg.* 104, 506–512. <http://thejns.org/doi/abs/10.3171/jns.2006.104.4.506>

- [29] Schuurman, P.R., et al., 2000. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. *N. Engl. J. Med.* 342, 461–468. DOI: 10.1056/NEJM200002173420703
- [30] Hariz, M.I., et al., 1999. Tolerance and tremor rebound following long-term chronic thalamic stimulation for Parkinsonian and essential tremor. *Stereotact. Funct. Neurosurg.* 72, 208–218. DOI:10.1159/000029728
- [31] Schuurman, P., et al., 2008. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. *Mov. Disord.* 23, 1146–1153. DOI: 10.1002/mds.22059
- [32] Berardelli, A., et al., 1998. The pathophysiology of primary dystonia. *Brain* 121, 1195–1212. DOI: <http://dx.doi.org/10.1093/brain/121.7.1195> 1195-1212
- [33] Bressman, S., 2004. Dystonia genotypes, phenotypes and classification. *Adv. Neurol.* 94, 101–107. doi:10.1001/archneur.61.11.1805-a.
- [34] Nutt, J., et al., 1988. Epidemiology of focal and generalized dystonia in Rochester, MN. *Mov. Disord.* 3, 188–194. DOI: 10.1002/mds.870030302
- [35] Burke, R., et al., 1986. Torsion dystonia: a double blind, prospective trial of high-dosage trihexyphenidyl. *Neurology* 36, 160–164. doi: <http://dx.doi.org/10.1212/WNL.36.2.160>
- [36] Greene, P., et al., 1988. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. *Adv. Neurol.* 50, 547–556. DOI: 10.1002/mds.870030107
- [37] Jankovic, J., 2006. Treatment of dystonia. *Lancet Neurol.* 5, 864–872. Kartha, N., 2006. Dystonia. *Clin. Geriatr. Med.* 22, 899–914 vii. doi:10.1016/S1474-4422(06)70574-9
- [38] Mejia, N., et al., 2005. Long-term botulinum toxin efficacy, safety and immunogenicity. *Mov. Disord.* 20, 592–597. DOI: 10.1002/mds.20376
- [39] Kupsch, A., et al., 2006. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. *N. Engl. J. Med.* 355, 1978–1990. DOI: 10.1056/NEJMoa063618
- [40] Vidailhet, M., et al., 2005. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. *N. Engl. J. Med.* 352, 459–467. DOI: 10.1056/NEJMoa042187
- [41] Holloway, K., et al., 2006. Deep brain stimulation for dystonia: a meta-analysis. *Neuromodulation* 9, 253–261. DOI: 10.1111/j.1525-1403.2006.00067.x
- [42] Chingiz Shashkin, Berik Zhetpisbayev, R. Abdulguzhina, Eugeny Zhukov, “Stereotactic biopsy of the brain tumors”, *Journal “Neurosurgery and Neurology of Kazakhstan” №4 (33), 2013. P. 23-25.*

**С. К. Акшулаков, Ч. С. Шашкин, Е. Т. Махамбетов,
Б. Д. Джамантаева, В. К. Ахметжанов, А. С. Шпеков**

«Ұлттық нейрохирургия орталығы» АҚ, Астана, Қазақстан

ҚОЗҒАЛЫС БҰЗЫЛЫСТАРЫН ЕМДЕУДЕ МИДЫ ТЕРЕҢ СТИМУЛЯЦИЯЛАУ

Аннотация. Миды терең стимуляциялау (МТС) тереңде орналасқан ядроларды электр арқылы стимуляциялаудан тұрады. Электродтар қажетті нысанаға ендіріледі, алайда стимуляциялау параметрлері оң әсерлерді арттыру мен жанама әсерлерді азайту үшін өзгертілуі мүмкін. МТС әдісі көбіне Паркинсон ауруы, эссенциалды тремор және дистонияны емдеуде қолданылады. Паркинсон ауруы кезіндегі діріл мен сіреспе әсіресе субталамус ядросын стимуляциялау кезінде емдеуге келеді. Таламустың вендральды ядросын стимуляциялау эссенциалды треморды емдеудің айтарлықтай тиімді әдісі. Бозғылт шарды стимуляциялау өзінің тиімділігін жайылып кеткен бастапқы дистония, бастапқы-сегментарлық дистония, цервикальды дистония, блефароспазма, Мерж синдромы, тардивті дистониялар және екіншілікті дистонияның бірқатар формалары кезінде көрсетті.

Ұлттық нейрохирургия орталығында 2013–2015 жылдар аралығында қозғалыс бұзылыстары бар 128 пациентке операция жасалды. Оның ішінде 10 пациент Паркинсон ауруы, 10-ы дистония, 1-уі эссенциалды тремор диагнозымен операцияға алынды. Еркектер саны 57, әйелдер 72. Пациенттердің орта жасы 51 жасты құрады. Паркинсон ауруы бойынша операция жасалған пациенттердің қимыл – қозғалыс функцияларының айтарлықтай жақсаруы 2013 жылы 65%, 2014 жылы 71%, 2015 жылы 92% дейін артты.

Дистониясы бар пациенттерді МТС емдеу спазмдық қисықмойында айтарлықтай тиімдірек болды, алайда екіншілікті сегментарлық және жайылып кеткен дистонияда тиімділігі айтарлықтай аз болды.

Ұлттық нейрохирургия орталығында 3 жыл бойы МТС әдісімен қозғалыс бұзылыстары бар пациенттерді емдеу бағдарламасы жүргізіліп келеді.

Түйін сөздер: миды терең стимуляциялау, Паркинсон ауруы, дистония тремор, хирургиялық емдеу.

**С. К. Акшулаков, Ч. С. Шашкин, Е. Т. Махамбетов,
Б. Д. Джамантаева, В. К. Ахметжанов, А. С. Шпеков**

АО «Национальный центр нейрохирургии», Астана, Казахстан

ГЛУБИННАЯ СТИМУЛЯЦИЯ ГОЛОВНОГО МОЗГА В ЛЕЧЕНИИ ДВИГАТЕЛЬНЫХ РАССТРОЙСТВ

Аннотация. Глубинная стимуляция головного мозга (ГСГМ) заключается в электрической стимуляции глубинных ядер. Электроды вживляются в необходимую цель, однако параметры стимуляции могут изменяться для того, чтобы увеличить положительные эффекты и уменьшить побочные. Наиболее часто методом ГСГМ лечатся болезнь Паркинсона, эссенциальный тремор и дистония.

Тремор и ригидность при болезни Паркинсона особенно поддается лечению стимуляцией субталамического ядра. Стимуляция вентрального ядра таламуса – наиболее эффективный метод лечения эссенциального тремора. Стимуляция бледного шара показала свою эффективность при первично-генерализованной дистонии, первично-сегментарной дистонии, цервикальной дистонии, блефароспазме, синдроме Мержа, тардивной дистонии и некоторых формах вторичной дистонии.

В Национальном центре нейрохирургии были оперированы 128 пациентов с двигательными расстройствами в период с 2013 по 2015 годы. Из них 117 пациентов было оперировано с диагнозом болезнь Паркинсона, 10 - дистония, 1 - эссенциальный тремор. Мужчин было 57 и 72 женщины. Средний возраст пациента составил 51 год. Значительное улучшение моторных функций у пациентов, оперированных по поводу болезни Паркинсона, увеличилось 65% в 2013 и 71% в 2014 до 92% в 2015. Лечение ГСГМ пациентов с дистонией было значительно эффективно при спастической кривошеей, но менее эффективно у пациентов с вторичной сегментарной и генерализованной дистонией.

В Национальном центре нейрохирургии на протяжении 3 лет проводится программа лечения пациентов с двигательными расстройствами методом ГСГМ.

Ключевые слова: глубинная стимуляция головного мозга, болезнь Паркинсона, дистония, тремор, хирургическое лечение.

Publication Ethics and Publication Malpractice in the journals of the National Academy of Sciences of the Republic of Kazakhstan

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

Submission of an article to the National Academy of Sciences of the Republic of Kazakhstan implies that the described work has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. In particular, translations into English of papers already published in another language are not accepted.

No other forms of scientific misconduct are allowed, such as plagiarism, falsification, fraudulent data, incorrect interpretation of other works, incorrect citations, etc. The National Academy of Sciences of the Republic of Kazakhstan follows the Code of Conduct of the Committee on Publication Ethics (COPE), and follows the COPE Flowcharts for Resolving Cases of Suspected Misconduct (http://publicationethics.org/files/u2/New_Code.pdf). To verify originality, your article may be checked by the Cross Check originality detection service <http://www.elsevier.com/editors/plagdetect>.

The authors are obliged to participate in peer review process and be ready to provide corrections, clarifications, retractions and apologies when needed. All authors of a paper should have significantly contributed to the research.

The reviewers should provide objective judgments and should point out relevant published works which are not yet cited. Reviewed articles should be treated confidentially. The reviewers will be chosen in such a way that there is no conflict of interests with respect to the research, the authors and/or the research funders.

The editors have complete responsibility and authority to reject or accept a paper, and they will only accept a paper when reasonably certain. They will preserve anonymity of reviewers and promote publication of corrections, clarifications, retractions and apologies when needed. The acceptance of a paper automatically implies the copyright transfer to the National Academy of Sciences of the Republic of Kazakhstan.

The Editorial Board of the National Academy of Sciences of the Republic of Kazakhstan will monitor and safeguard publishing ethics.

Правила оформления статьи для публикации в журнале смотреть на сайте:

www.nauka-nanrk.kz

ISSN 2518-1629 (Online), ISSN 2224-5308 (Print)

<http://www.biological-medical.kz/index.php/ru/>

Редактор *М. С. Ахметова*

Верстка на компьютере *Д. Н. Калкабековой*

Подписано в печать 14.10.2016.

Формат 60x881/8. Бумага офсетная. Печать – ризограф.

11,75 п.л. Тираж 300. Заказ 5.